

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on November 9, 2006

PATENT  
Attorney Docket No.: 082368-007600US  
Client Reference No.: ONC-A0305P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Aaron Hokamura/

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

NAKAMURA and FURUKAWA

Application No.: 10/572,932

Filed: September 14, 2004

For: METHOD FOR DIAGNOSING  
HEPATOCELLULAR CARCINOMAS

Confirmation No.: 5301

Examiner:

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AA - AD are enclosed. A copy of reference AE is not provided since it was cited in an International Search Report in a corresponding application, and, as such, should have been provided directly by the WIPO under the exchange program between the USPTO, the EPO and the JPO. A copy of the Search Report is attached.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
80813010 v1

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/572,932
				Filing Date	September 14, 2004
				First Named Inventor	Nakamura, Yusuke
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	062368-007600US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	WO	03/006578	A2	01-30-2003	Board of Trustees of the University of Illinois		<input type="checkbox"/>
	AB	WO	03/025228	A1	03-27-2003	Proteologics, Inc.		<input type="checkbox"/>
	AC	WO	03/027143	A2	04-03-2003	Japan as represented by The President of the University of Tokyo; and Oncotherapy Science, Inc.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AD	OKABE, Hiroshi et al.; "Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression"; <i>Cancer Research</i> 61:2129-2137 (March 1, 2001)	<input type="checkbox"/>
	AE	THOMPSON, J.D.; "Applications of antisense and siRNAs during preclinical drug development"; <i>Drug Discov. Today</i> 7(17):912-917 (September 1, 2002)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.